1 Inclusion criteria were endometrial cancer with cervical stromal invasion, FIGO 2009 stage II, III, or IV. Exclusion criteria were invasive synchronous cancer and receipt of neoadjuvant therapy.

Duska noted that the PD-L1 inhibitor pembrolizumab has shown efficacy in the treatment of recurrent or metastatic cervical ...

Study presented at ESGO 2025 highlights the accuracy of preoperative tumour size assessment in stage IB2 cervical cancer and ...

"Our findings suggest that, in the condition of negative sentinel lymph nodes, omitting pelvic lymphadenectomy does not ...

Karnataka is at the forefront of a historic initiative to eliminate cervical cancer through a collective and strategic effort ...

A pembrolizumab (Keytruda) combination led to an overall survival (OS) boost in patients with newly diagnosed, previously ...

for patients with high-risk locally advanced cervical cancer; in other words, those with stage III to IVA disease, according to the FIGO scale. Cervical cancer is on the decline in the US thanks ...